Evidence map›Paper›PMID 39100526›Full record

ArticleOpen forum infectious diseases2024

Similar Viral and Immune Characteristics of Kaposi Sarcoma in ART-treated People Living With HIV and Older Patients With Classic Kaposi Sarcoma.

Léna Royston, Aude Jary, Carolina A Berini, Tsoarello Mabanga, John Lin, Amélie Pagliuzza, Nicolas Chomont, Ivan V Litvinov, Alexandra Calmy, Valentin Leducq and 4 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Léna RoystonChronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
Aude JarySorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Laboratoire de Virologie, Paris, France.ORCID https://orcid.org/0000-0002-1952-6729
Carolina A BeriniChronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
Tsoarello MabangaChronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
John LinChronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
Amélie PagliuzzaCentre de Recherche du CHUM, Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC, Canada.
Nicolas ChomontCentre de Recherche du CHUM, Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC, Canada.ORCID https://orcid.org/0000-0001-9747-5018
Ivan V LitvinovResearch Institute of the McGill University Health Centre, Infectious Diseases and Immunity in Global Health Program, Montreal, QC, Canada.
Alexandra CalmyHIV Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-1137-6826
Valentin LeducqSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Laboratoire de Virologie, Paris, France.ORCID https://orcid.org/0000-0002-6817-6227
Vincent CalvezSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Laboratoire de Virologie, Paris, France.
Anne-Geneviève MarcelinSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Laboratoire de Virologie, Paris, France.
Stéphane IsnardChronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.ORCID https://orcid.org/0000-0001-6249-1659
Jean-Pierre RoutyChronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.ORCID https://orcid.org/0000-0001-9897-7589

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Reemergence of human herpesvirus 8 (HHV-8)-induced Kaposi sarcoma (KS) in people living with HIV (PLWH) despite antiretroviral therapy (ART) poses a clinical challenge because they already have favorable CD4 T-cell numbers and undetectable viral loads. We observed that clinical presentation in PLWH on ART resembled classic KS found in older HIV-uninfected patients and hypothesized that immunosenescence may thus play a role in occurrence of KS on ART. We compared viral and immune factors implicated in the development of KS in ART-treated PLWH (HIV KS) and HIV-uninfected classic KS patients (cKS), compared to controls without KS (HIV Control, cControls respectively). Methods: Plasma, peripheral blood mononuclear cell, and skin tissues were obtained from 11 HIV KS and 11 cKS patients and 2 groups of age-matched controls. Results: HIV KS participants were younger than cKS (aged 53 vs 75 years). HHV-8 genotypes did not differ between groups. Despite the younger age and a lower CD4/CD8 ratio, activated, exhausted, and senescent T-cell frequencies were similar between HIV KS and cKS. Anti-HHV-8 immunoglobulin G levels were higher and circulating HHV-8 DNA lower in HIV KS compared with cKS. Circulating platelet-derived growth factors AA-BB and granulocyte colony-stimulating factors were higher in HIV KS We observed similar levels of HHV-8 DNA and PD-1 expression in skin lesions from HIV KS and cKS patients. Conclusions: Altogether, early immune senescence could be involved in the development of KS in ART-treated PLWH. Higher anti-HHV-8 immunoglobulin G levels could be linked with lower circulating viral load. Such insights should help developing therapeutical strategies to prevent development and treat KS in PLWH on ART.

Indexed as

cellular immunityhuman herpesvirus 8human immunodeficiency virushumoral immunityKaposi sarcoma

Identifiers

PMID39100526
PMCPMC11295207

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.